Switching Between Intravenous and Oral P2Y₁₂ Inhibition: Easier Said Than Done

JACC Cardiovasc Interv. 2023 Jan 9;16(1):47-49. doi: 10.1016/j.jcin.2022.11.014.

Author

Affiliation

¹ University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, USA. Electronic address: usman-baber@ouhsc.edu.

PMID: 36599586
DOI: 10.1016/j.jcin.2022.11.014

No abstract available

Keywords: acute coronary syndrome; cangrelor; platelet inhibition.

Publication types

Editorial
Comment

MeSH terms

Acute Coronary Syndrome* / drug therapy
Adenosine Monophosphate
Administration, Intravenous
Humans
Percutaneous Coronary Intervention*
Platelet Aggregation Inhibitors / therapeutic use
Purinergic P2Y Receptor Antagonists / adverse effects
Receptors, Purinergic P2Y12
Ticagrelor
Treatment Outcome

Substances

Platelet Aggregation Inhibitors
Ticagrelor
Purinergic P2Y Receptor Antagonists
Adenosine Monophosphate
Receptors, Purinergic P2Y12